JP2019517498A - 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 - Google Patents

再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 Download PDF

Info

Publication number
JP2019517498A
JP2019517498A JP2018562918A JP2018562918A JP2019517498A JP 2019517498 A JP2019517498 A JP 2019517498A JP 2018562918 A JP2018562918 A JP 2018562918A JP 2018562918 A JP2018562918 A JP 2018562918A JP 2019517498 A JP2019517498 A JP 2019517498A
Authority
JP
Japan
Prior art keywords
antibody
nivolumab
ctla
weeks
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517498A5 (enExample
Inventor
マリーナ・チャイカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019517498A publication Critical patent/JP2019517498A/ja
Publication of JP2019517498A5 publication Critical patent/JP2019517498A5/ja
Priority to JP2022007372A priority Critical patent/JP2022058699A/ja
Priority to JP2024141986A priority patent/JP2024167282A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018562918A 2016-06-03 2017-06-02 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 Pending JP2019517498A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022007372A JP2022058699A (ja) 2016-06-03 2022-01-20 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
JP2024141986A JP2024167282A (ja) 2016-06-03 2024-08-23 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345463P 2016-06-03 2016-06-03
US62/345,463 2016-06-03
PCT/US2017/035808 WO2017210631A1 (en) 2016-06-03 2017-06-02 Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022007372A Division JP2022058699A (ja) 2016-06-03 2022-01-20 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体

Publications (2)

Publication Number Publication Date
JP2019517498A true JP2019517498A (ja) 2019-06-24
JP2019517498A5 JP2019517498A5 (enExample) 2020-07-09

Family

ID=59054317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018562918A Pending JP2019517498A (ja) 2016-06-03 2017-06-02 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
JP2022007372A Pending JP2022058699A (ja) 2016-06-03 2022-01-20 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
JP2024141986A Pending JP2024167282A (ja) 2016-06-03 2024-08-23 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022007372A Pending JP2022058699A (ja) 2016-06-03 2022-01-20 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
JP2024141986A Pending JP2024167282A (ja) 2016-06-03 2024-08-23 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体

Country Status (6)

Country Link
US (3) US20190292260A1 (enExample)
EP (2) EP3463454A1 (enExample)
JP (3) JP2019517498A (enExample)
KR (1) KR20190015407A (enExample)
CN (1) CN109475634A (enExample)
WO (1) WO2017210631A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873402C (en) * 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR102740444B1 (ko) * 2015-04-17 2024-12-10 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
PT3377534T (pt) 2015-11-18 2025-07-10 Bristol Myers Squibb Co Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4
KR20190015407A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
JP2021519771A (ja) * 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
WO2020081783A2 (en) * 2018-10-18 2020-04-23 Medimmune, Llc Anti-ox40, anti-pd-l1 and anti-ctla-4 antibodies for treating tumors
JP2022505647A (ja) * 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
JP2022527177A (ja) * 2019-03-28 2022-05-31 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置する方法
AU2022205648A1 (en) * 2021-01-08 2023-08-24 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-gm1 antibody
WO2025210571A1 (en) * 2024-04-05 2025-10-09 Astrazeneca Ab Treatment of limited-stage small-cell lung cancer with pd-l1 inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR102636539B1 (ko) 2014-10-29 2024-02-13 파이브 프라임 테라퓨틱스, 인크. 암에 대한 조합 요법
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR20190015407A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 3(Suppl 2), JPN6021019222, 2015, pages 376, ISSN: 0004597150 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 34(15_suppl), JPN6021019223, 20 May 2016 (2016-05-20), pages 100, ISSN: 0004597151 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 34(15_suppl), JPN6021019224, 20 May 2016 (2016-05-20), pages 3001, ISSN: 0004597152 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 34(15_suppl), JPN6021036501, 20 May 2016 (2016-05-20), pages 3060, ISSN: 0004597153 *

Also Published As

Publication number Publication date
JP2024167282A (ja) 2024-12-03
WO2017210631A1 (en) 2017-12-07
US20190292260A1 (en) 2019-09-26
EP4386005A3 (en) 2024-09-04
EP3463454A1 (en) 2019-04-10
US20210403569A1 (en) 2021-12-30
US11767361B2 (en) 2023-09-26
US20240052035A1 (en) 2024-02-15
KR20190015407A (ko) 2019-02-13
EP4386005A2 (en) 2024-06-19
JP2022058699A (ja) 2022-04-12
WO2017210631A9 (en) 2018-01-11
CN109475634A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
US11767361B2 (en) Method of treating lung cancer
JP2025029025A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法
JP2022071038A (ja) Ｐｄ－１／ｐｄ－ｌ１シグナル伝達を破壊することによる癌免疫療法
CN106573977B (zh) 针对ceacam1的人源化抗体
JP2025081454A (ja) 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
US20180155429A1 (en) Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
KR20220133243A (ko) 항 tigit 길항제 항체를 이용한 암의 치료 방법
US20240124589A1 (en) Methods of treating urothelial carcinoma using an anti-pd-1 antibody
JP2020507596A (ja) 膀胱癌の抗ｐｄ−ｌ１抗体治療
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
US20250179182A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody drug conjugate
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210921